HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

Clinical trials for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) explained in plain language.

Never miss a new study

Get alerted when new HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) trials appear

Sign up with your email to follow new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 2 Completed 1

New drug aims to stop debilitating nosebleeds in rare disease

Disease control Recruiting now

This is the first human trial for a new drug called TER-1754, designed for people with hereditary hemorrhagic telangiectasia (HHT), a disorder that causes frequent, severe nosebleeds and other bleeding problems. The main goal is to find a safe dose and see if the drug can reduce …

Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

Phase: PHASE1 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

Get alerted when new HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) trials appear

New drug aims to stop debilitating nosebleeds in rare disease